On the morning of July 20, a project of Aurobindo Pharma Taizhou Co., Ltd. started construction in China Medical City (CMC). With a total investment of USD 100 million, the project has an annual production capacity of 3.5 billion tablets and 500 million capsules, and will generate annual sales of RMB 3 billion after put into production.
Aurobindo Pharma Taizhou Co., Ltd. is invested by the headquarters of Aurobindo Pharma Limited in India. Aurobindo Pharma Limited is a large multinational corporation and the second largest listed pharmaceutical company in India with 25 factories or offices spreading over China, the United States, Europe, South America and South Africa. The company operates business in fields such as central nervous system, anti-HIV, angiocarpy, diabetes, gastroenterologicals, and cephalosporins. By the end of 2017, 350 generic drug applications of Aurobindo Pharma had been approved in the United States, exceeding the total number of applications of all Chinese pharmaceutical companies approved there. The company has sold preparations amounting to USD 2.6 billion in the American market, and ranks world first in terms of the sales of APIs, making it a leading manufacturer in the pharmaceutical field.